Concepedia

Barry W. Miller

BW

Statistics

Publications

13

Citations

347

H-Index

12

Active since

1976

Affiliations

Thomas Jefferson National Accelerator Facility(Current)

United States Food and Drug Administration

Istituto Nazionale di Fisica Nucleare, Sezione di Genova

National Cancer Institute

University of Glasgow

Barry W. Miller is an author at Thomas Jefferson National Accelerator Facility specializing in medicine, cancer immunotherapy, and chemistry.

Publications per year

1976–2020

13

Publications

13

Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia

Steven T. Bird, Fang Tian, Natasha Flowers et al. · JAMA Oncology · 2019 · 64 citations · Full text

, , +14

Neutrophil defect associated with malignant infantile osteopetrosis.

Claire Beard, L. Lyndon Key, Peter E. Newburger et al. · PubMed · 1986 · 55 citations

, , +9

U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Hyon-Zu Lee, Barry W. Miller, Virginia E. Kwitkowski et al. · Clinical Cancer Research · 2014 · 41 citations

, , +15

A 1,5-diazabicyclo[3.3.3]undecane derivative with almost planar bridgehead nitrogens

Roger W. Alder, Nigel C. Goode, Trevor J. King et al. · Journal of the Chemical Society Chemical Communications · 1976 · 40 citations

, , +6

The CLAS12 high threshold Cherenkov counter

Y. G. Sharabian, Volker Burkert, A. S. Biselli et al. · Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment · 2020 · 25 citations · Full text

, , +10

1–5 of 13